About this episode

The episode discusses the results of the retatrutide phase 3 trial and its implications for weight loss and cardiometabolic health.

Dr. Spencer Nadolsky and Karl sit down with David W, a nurse practitioner who was actually enrolled in the Triumph 1 retatrutide phase 3 trial, to break down data just presented at the American Diabetes Association conference showing average weight loss of up to 30 percent and cardiometabolic benefits that go well beyond anything tirzepatide or semaglutide produce on their own. David went from 240 pounds to 167 in the trial and walks through exactly what the experience felt like from the inside while Spencer and Karl explain what the numbers mean for patients and clinicians waiting for this drug to reach the market.

Explore listener stats, chart rankings, contacts and more on the Docs Who Lift podcast page.